Bitopertin
Bitopertin (pronounced as bi-toe-per-tin) is a novel pharmaceutical drug currently under development by Roche, a Swiss multinational healthcare company. It is primarily being investigated for its potential use in the treatment of schizophrenia and related psychiatric disorders.
Etymology
The name "Bitopertin" is a coined term, with no known etymology. It is a common practice in the pharmaceutical industry to create unique names for new drugs that do not have any specific meaning in any language.
Pharmacology
Bitopertin is a glycine reuptake inhibitor. It works by increasing the levels of glycine in the brain. Glycine is a neurotransmitter that plays a crucial role in the functioning of the nervous system. By increasing the levels of glycine, Bitopertin is believed to help reduce the symptoms of schizophrenia and other psychiatric disorders.
Clinical Trials
Bitopertin is currently in the late stages of clinical trials. The drug has shown promise in early trials, but further research is needed to confirm its efficacy and safety. If approved, Bitopertin would be the first glycine reuptake inhibitor to be used in the treatment of schizophrenia.
Related Terms
- Glycine
- Schizophrenia
- Psychiatric disorders
- Roche
- Pharmaceutical drug
- Clinical trials
- Nervous system
See Also
External links
- Medical encyclopedia article on Bitopertin
- Wikipedia's article - Bitopertin
This WikiMD article is a stub. You can help make it a full article.
Languages: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski